Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1 | Caris Life Sciences
Portal
Order
Home / Research / Publications / Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1

Publications

Back

Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1

– Caris Life Sciences

Poster

Background

Liver is the most common metastatic site for various tumors and associates with poor prognosis. To understand LM as distinct molecularly from other origins such as CRC, NSCLC, BC and GE, we compared a large cohort of LM with local disease (LD) and other metastases (OM).

Download Publication

Discover
More

  • Tumor Mutational Burden Is Site Specific in Non–Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases

    – Caris Life Sciences

    Manuscript

    PURPOSE Tumor mutational burden (TMB) is a developing biomarker in non–small-cell lung cancer (NSCLC). Little is known regarding differences between TMB and sample location, histology,… […]

  • Characterization of tumor mutation load (TML) in solid tumors

    – Caris Life Sciences

    Poster

    Background: Rapid advances in immunotherapy have created a need for biomarkers to improve patient treatment selection. TML is proposed as a potential predictive biomarker due… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)